Document center

Report on Research Assessment

Published on | 9 months ago

Programmes Enhancing EU R&I SwafS

This report maps the contributions of 30 projects funded through Horizon 2020 and Horizon Europe to understanding and enacting the reform of research assessment. It approaches the reform of research assessment practices through the principles enshrined in the agreement on reforming research assessment. The report identifies relevant activities and results, analyses their role in contributing to the wider cultural change underpinning the movement towards reformed research assessment, disseminates promising practices and explores the potential for further work in this area. The sources reviewed include project documentation, qualitative survey responses by the coordinators and information from a small number of interviews and informal conversations, along with participation in events. (from executive summary of the study)

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.